Skip to main content

Table 4 Univariate analysis of overall survival (OS)

From: Comparison of weekly administration of cisplatin versus three courses of cisplatin 100 mg/m2 for definitive radiochemotherapy of locally advanced head-and-neck cancers

  At 1 year (%) At 3 years (%) P
Radiochemotherapy regimen
 Cisplatin weekly (N = 75) 71 45  
 Cisplatin 100 mg/m2 (N = 58) 83 60 0.026
Age
 ≤56 years (N = 67) 77 54  
 ≥57 years (N = 66) 74 49 0.50
Gender
 Female (N = 29) 89 70  
 Male (N = 104) 72 47 0.050
ECOG Performance score
 0–1 (N = 115) 78 56  
 2 (N = 18) 61 14 0.006
Primary tumor site
 Oropharynx (N = 69) 78 61  
 Hypopharynx (N = 19) 53 21  
 Larynx (N = 30) 83 59  
 Oral cavity/Floor of mouth (N = 15) 80 29 <0.001
T-category
 T1–2 (N = 16) 81 63  
 T3–4 (N = 117) 75 50 0.85
N-category
 N0-2a (N = 66) 79 60  
 N2b-3 (N = 67) 73 42 0.14
Histologic grading
 G 1–2 (N = 85) 78 52  
 G3 (N = 48) 73 51 0.47
Cumulative cisplatin dose
 ≤ 200 mg/m2 (N = 85) 69 46  
 > 200 mg/m2 (N = 48) 87 61 0.13
  1. After Bonferroni correction for multiple tests, p-values of <0.006 were considered significant
  2. Bold values represent significant p-values